GBA's "2021 Stock Phantasma"

There some places in the city especially the meat packing district where you just can't say
Long Straddle Strangle!

I just can't get my head around options at all. Never could. One time I lost everything you can't just roll them forward that a lie nobody is there.

The idea of going to zero. I'm not into it. Time value! I hold forever sometimes!!!! The idea of betting a little to win a lot. Not into it. Step up.
Make a one way bet and stop the damn nonsense half and half straddle... Oh if this happens I'll still capture so and so...get some balls!
 
stonedinvestor said:
I hold forever sometimes!!!!
More...

And we have a portfolio just for that.
Gummies-4-Grandma.

But.... just because you don't play options, does not mean you should not have them in your bag-of-tools when figuring things out.
You think those MM's are stupid?!
They're not.
Sure, they play what's given to them, they balance it all out like a good bookie will... but it's in that "giving" that the secrets reside.
-vz
 
Stoney!!!!

Look at Fluor.
Up 6% on a great report.
That should help GVA

Good job on DKNG.
$52
Note it's staying in that range I said it would.
For now at least.
Monthly revenue/user way up. That's a good sign.
Its a good stock. :thumbsup:

vanzandt said:
Which one will have a 10% gain first?
FLR to $18.30
or
GVA to 43.25
?????

200w.gif
More...
 
Last edited:
DraftKings EPS misses by $0.18, beats on revenue, boosts full year revenue guidance-- Boost is a word that means " up "
Aug. 06, 2021 7:04 AM ETDraftKings Inc. (DKNG)DraftKings Inc. (DKNG)WAKE UP ROBIN HOODERSDraftKings(NASDAQ:DKNG): Q2 Non-GAAP EPS of -$0.26; GAAP EPS of -$0.76misses by $0.18.
  • Revenue of $298M (+320.1% Y/Y)beats by $50.78M. :wtf:
  • Monthly Unique Payers for B2C segment increased 281% compared to the second quarter of 2020. :cool:
  • Average Revenue per MUP was $80 in the second quarter of 2021 representing a 26% increase versus the same period in 2020.:rolleyes:
  • The company is raising its FY2021 revenue guidance from a range of $1.05M-$1.15B to a range of $1.21B-$1.29B vs. consensus of $1.18B.:strong:
LETS GET MEME!! $54 NOW $57 AT 2:00!!!!<-------:thumbsup:
 
YESTERDAY GUMMYBEAR ADVISORS REALIZED, ADVISED AND RECOGNIZED A 79% GAIN IN 1 DAY-!!! What Will gummybear Do For You Today-?

Top Gainers (NYSE, NASDAQ)
  • Stock
    Today
  • No 1 gainer> Score Media and Gaming Inc - Class A (Sub Voting)
    SCR+ 79.55%!!!!!
 
gummybear advisors co-investing Chief in state Van told you to buy FLUOR and you went and bought some white stuff at the market!! No... This Fluor!

Fluor EPS beats by $0.24, beats on revenue, boosts full year adjusted EPS guidance- Beats means better than /greater than!!
Aug. 06, 2021 6:54 AM ETFluor Corporation (FLR)Fluor Corporation (FLR)
  • Fluor(NYSE:FLR): Q2 Non-GAAP EPS of $0.32beats by $0.24; GAAP EPS of -$0.08misses by $0.12.
  • Revenue of $3.24B (-13.1% Y/Y)beats by $40M.:cool:
  • Second quarter new awards were $1.4 billion, and ending consolidated backlog was $21.1 billion, down from $23.8 billion last quarter.
  • Fluor’s cash and marketable securities at the end of the quarter were $2.7 billion.
  • The Company raised full year adjusted EPS guidance to $0.60 to $0.80 per diluted share (prior: $0.46-$0.71) vs. consensus of $0.56.:strong:
These aren't slight beats folks... These are outstanding earnings!!!
 
Possible gummy)-EXEL

  • Exelixis'(NASDAQ:EXEL)Q2 2021 net income surged ~44% year-over-year to $96.1M ($0.30 per diluted share) due in large part to the approval of the renal cell carcinoma ("RCC") therapy Cabometyx (cabozantinib) in January 2021.
  • Revenue in the quarter soared 48% compared to the prior-year period to $385.2M. of that figure, $284.2M came from Cabomeytx.
  • Cabometyx is approved as a first-line RCC treatment in combination with Opdivo (nivolumab).
  • As a result of the strong performance of Cabometyx in the quarter,Exelixis raised its net product and total revenue guidance for 2021as follows: net product, $1.05B-$1.15B; total revenue of $1.3B-$1.4B.
  • Earlier today, the FDA granted Priority Review for the company'ssNDA for Cabometyx for thyroid cancer.
EXEL>$17 1/2
 
--SailPoint initiated with an Outperform at Wolfe Research 08:25 SAIL

--Joint Corp. price target raised to $150 from $70 at Lake Street 08:04 JYNT Lake Street analyst Brooks O'Neil raised the firm's price target on Joint Corp. to $150 from $70 and keeps a Buy rating on the shares after the company delivered "exceptional" Q2 results and increased FY21 guidance for revenue and AEBITDA. Though he believe the Joint is "sticking to their playbook of being conservative," he believes the company is "firing on all cylinders" and he expects outsized growth over the coming years to precede "significant profitability," O'Neil tells investors.

--U.S. Physical Therapy price target raised to $139 from $130 at Barrington 08:03 USPH

--Grid Dynamics price target raised to $30 from $23 at Needham 08:00 GDYN Needham analyst Mayank Tandon raised the firm's price target on Grid Dynamics to $30 from $23 and keeps a Buy rating on the shares. The company reported an "outstanding" Q2 that topped expectations across the board and the management issued an "upbeat" Q3 outlook calling for 35% organic growth, the analyst tells investors in a research note. Tandon adds that he was particularly impressed with management's client diversification efforts and the five new organic logo wins in Q2 across industry segments.

--Grid Dynamics price target raised to $25 from $20 at Canaccord GDYN
 
Aemetis receives final permit to build next 21 miles of Phase 2 Biogas pipeline 08:10 AMTX Aemetis announced the final permit has been approved to begin construction of the next 21 miles of the Aemetis Biogas Phase 2 pipeline in Stanislaus County, Calif. This significant project milestone allows the installation of biogas pipeline in Stanislaus County roads for construction of a pipeline that extends the existing 4-mile pipeline by an additional 21 miles. The pipeline will convey conditioned biogas from dairies to the Company's centralized gas cleanup facility which is currently under construction at the Aemetis Advanced Fuels Keyes ethanol plant. At the Keyes plant, the biogas will be upgraded to negative carbon intensity Renewable Natural Gas for use as transportation fuel in trucks and buses.

BofA points to five reasons to upgrade Leslie's to Buy 07:38 LESL As previously reported, BofA analyst Elizabeth Suzuki upgraded Leslie's to Buy from Neutral with a $36 price target, highlighting five reasons for her raised rating. Residential pools will likely stay open longer this year; commodity inflation, particularly chlorine, is likely to provide additional upside to the company's same-store sales growth; the company has several initiatives for next pool season; new pool demand continues "running at a strong clip"; and she views the stock's current valuation "as attractive as it's been since IPO," Suzuki said.<--- YES!

Confluent price target raised to $42 from $37 at Deutsche Bank 06:56 CFLT Deutsche Bank analyst Patrick Colville raised the firm's price target on Confluent to $42 from $37 and keeps a Hold rating on the shares post the "solid" Q2 results.

Confluent price target raised to $51 from $45 at Citi 05:28 CFLT Citi analyst Tyler Radke raised the firm's price target on Confluent to $51 from $45 and keeps a Neutral rating on the shares. Confluent's first quarter as a public company "was stellar," with revenue growth 20 points faster than consensus, and a reacceleration...
 
It looks like the momentum players are hitting DKNG pretty hard Stoney.
It may just take out $57.

The YETI!

You hated the YETI Stoney!

Remember this when it was $87

vanzandt said:
But when in doubt...

....buy the YETI.
;)
More...


Never hate the YETI!

stonedinvestor said:
Take that Cooler stock and shove it! -Yeti please... This is the new bag of choice.
More...

All-time high of $105.

Matt Reintjes, President and Chief Executive Officer, commented, “Demand and passion for the YETI brand remained robust during the second quarter. Net sales surged 45% during the period, driven by strong direct-to-consumer performance throughout the quarter including Mother’s Day and Father’s Day, significant year-over-year recoveries in channels such as wholesale that experienced outsized impacts during the pandemic, and a more than three-fold gain in our international business. This topline performance combined with better-than-planned operating margins fueled 66% earnings per share growth for the quarter.”
 
You must log in or register to reply here.
Back
Top